DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Moderna - 4 “ - 3 ” - 2 Jacqueline Miller - 2 BioNTech - 2 Dado Ruvic - 2 Patrick Wingrove - 2 Bill Berkrot - 2
Top related locs:
Moderna Switzerland South Africa Israel Denmark U.S Britain New York
Top related orgs:
Moderna - 4 ” Moderna - 4 CDC - 3 Prevention - 3 Pfizer - 3 World Health Organization - 2 WHO - 2 U.S . Centers for Disease Control - 2

Search resuls for: "” Moderna"


6 mentions found


☆ Covid-flu combination vaccine shows positive results in late-stage trial, Moderna says
  + stars: | 2024-06-10 | by ( Jen Christensen | ) edition.cnn.com   time to read: +5 min
CNN —There could be a combined Covid-19 and flu shot in our future, although it won’t be ready for this year’s flu season. On Monday, vaccine maker Moderna announced positive late-stage trial results for its Covid/flu combination vaccine it calls mRNA-1083. Other companies have been testing a combined Covid-flu vaccine, but Moderna is the first to announce positive late-stage trial results. The trial studied the vaccine in two different age groups with about 4,000 adults in each age category. Few people got the latest Covid shot, studies show.
Persons: ”, Francesca Ceddia, ” Ceddia, Covid, Spikevax, Moderna, Sue Peschin, Dr, Sanjay Gupta, Peschin, ” Peschin, “ Organizations: CNN, Moderna, Public, US Centers for Disease Control, Food, Covid, FDA, Alliance for Aging Research, CNN Health, CDC Locations: United States
☆ First Shot Administered in Moderna’s Combo COVID-19/Flu Vaccine Final Stage Trial
  + stars: | 2023-10-24 | by ( Cecelia Smith-Schoenwalder | Oct. | At P.M. | ) www.usnews.com   time to read: +1 min
Moderna on Tuesday announced that its combination shot for flu and COVID-19 is the first candidate to make it to late-stage trial. It “offers greater convenience and has the potential to lead to increased compliance with vaccine recommendations,” it added. The shots won’t be available for this respiratory virus season, as Moderna said it is targeting regulatory approval for the shot in 2025. Moderna earlier this month announced positive data from its earlier studies of the combo shot, finding that it produced an immune response similar to or greater than licensed flu shots and Moderna’s bivalent COVID-19 shot. “We are excited to move combination respiratory vaccines into Phase 3 development and look forward to partnering with public health officials to address the significant seasonal threat posed to people by these viruses.”
Persons: “, Moderna, bivalent, Stéphane Bancel Organizations: Moderna, Tuesday, Northern Hemisphere, Disease Control, ” Moderna Locations: Moderna
☆ Booking a COVID-19 Vaccine? Some Are Reporting Canceled Appointments or Insurance Issues
  + stars: | 2023-09-21 | by ( Associated Press | Sept. | At P.M. | ) www.usnews.com   time to read: +4 min
MILWAUKEE (AP) — Some people seeking the newest COVID-19 vaccine are running into high demand, insurance headaches and supply delays coast to coast. But some people have had to cancel appointments because their insurance hasn’t updated the billing codes to cover the vaccines. And in some places, there are no available nearby vaccines: A search in Juneau, Alaska, through the federal government’s website shows no available appointments within 100 miles. For others, the shots were covered by insurance without issue, but appointments were canceled by their pharmacy due to supply delays. Walgreens and CVS confirmed that delivery delays to some stores across the country had led to canceled appointments.
Persons: Cases, Alex Huseman, ” Huseman, Matt Blanchette, “, Pfizer spokespeople, Chris Ridley, Marwa Bakr, ” Bakr, Karen Ramos, ” Ramos, ”, Robert Wood Johnson Organizations: MILWAUKEE, for Disease Control, Prevention, Alaska Department of Health, CVS, Walgreens, ” Moderna, Pfizer, Associated Press, Associated Press Health, Science Department, Robert Wood Johnson Foundation, AP Locations: Juneau , Alaska, Moderna, Temecula , California, Caribbean, San Diego, Temecula
☆ Moderna, Pfizer say updated COVID shots generate strong response vs newer variant
  + stars: | 2023-09-06 | by ( Patrick Wingrove | ) www.reuters.com   time to read: +3 min
Moderna said its shot generated an 8.7-fold increase in neutralizing antibodies against BA.2.86 compared with an untreated natural antibody response in clinical trials in humans. Pfizer said its updated vaccine with partner BioNTech (22UAy.DE) elicited a strong antibody response against BA.2.86 in a preclinical study in mice. Moderna, Pfizer/BioNTech and relative newcomer to the COVID vaccine market Novavax (NVAX.O) have created versions of their shots aimed at the XBB.1.5 subvariant, the dominant variant through most of 2023. Moderna shares were down 1.6% and Pfizer shares were off nearly 3% in afternoon trading. The Omicron offshoot carries more than 35 mutations in key portions of the virus compared with XBB.1.5, the target of the updated shots.
Persons: Moderna, Jacqueline Miller, BioNTech, Cowen, Tyler Van Buren, Dado Ruvic, Patrick Wingrove, Michael Erman, Bill Berkrot Organizations: Pfizer, World Health Organization, WHO, U.S . Centers for Disease Control, Prevention, ” Moderna, Moderna, REUTERS, CDC, Omicron, U.S . Food, Drug Administration, Britain's Medicines, Healthcare, Agency, Reuters, Thomson Locations: Switzerland, South Africa, Israel, Denmark, U.S, Britain, New York, New Jersey
☆ Moderna says updated COVID vaccine is effective against newer variant
  + stars: | 2023-09-06 | by ( Patrick Wingrove | ) www.reuters.com   time to read: +2 min
[1/2] A vial and sryinge are seen in front of a displayed Moderna logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsSept 6 (Reuters) - Moderna (MRNA.O) on Wednesday said clinical trial data showed its updated COVID-19 vaccine will likely be effective against the highly-mutated BA.2.86 subvariant of the coronavirus that has raised fears of a resurgence of infections. The Omicron offshoot carries more than 35 mutations in key portions of the virus compared with XBB.1.5, the dominant variant through most of 2023 and the target of the updated shots. Moderna said it had shared the new finding on its vaccine with regulators and submitted it for peer review publication. European regulators have since backed the Pfizer/BioNTech shot, with Britain's Medicines and Healthcare products Regulatory Agency approving the vaccine on Tuesday, but have yet to make any announcements on Moderna’s updated vaccine.
Persons: Dado Ruvic, Jacqueline Miller, Moderna, COVID, BioNTech, Patrick Wingrove, Bill Berkrot Organizations: REUTERS, World Health Organization, WHO, U.S . Centers for Disease Control, Prevention, ” Moderna, CDC, Omicron, U.S . Food, Drug Administration, Pfizer, Moderna, Britain's Medicines, Healthcare, Agency, Reuters, Thomson Locations: The Massachusetts, Switzerland, South Africa, Israel, Denmark, U.S, Britain, New York
☆ Moderna says personalized mRNA cancer vaccine is effective for advanced melanoma
  + stars: | 2022-12-13 | by ( The Associated Press | ) www.nbcnews.com   time to read: +2 min
The company said a possible melanoma vaccine it is studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically removed. The drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in survival before the cancer returned in patients with advanced melanoma. “We are very excited, we are moving very quickly with Merck onto phase 3 for this study,” Moderna CEO Stephane Bancel told CNBC Tuesday morning. Like Spikevax, the potential skin cancer vaccine uses mRNA technology. The patient group that took the potential vaccine and Keytruda saw a 44% reduction in the risk of death or the cancer returning, the companies said.
0 next >>
Total: 6